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Purpose: Evaluation of the inﬂuence of long-term intravitreal anti–vascular endothelial
growth factor treatment on preexisting retinal microstructural alterations in patients with
diabetic macular edema.
Methods: Eyes with diabetic macular edema and a history of $ 20 intravitreal anti–
vascular endothelial growth factor (aﬂibercept and/or ranibizumab) injections were
included in this retrospective study. Primary outcome was the extent of disorganization of
retinal inner layers, alterations at the outer plexiform layer/Henle ﬁber layer junction, dis-
ruption of external limiting membrane/ellipsoid zone, disruption of retinal pigment epithe-
lium/Bruch complex, and retinal atrophy at baseline versus after $ 20 intravitreal injections
as visualized by spectral-domain optical coherence tomography images.
Results: Of 383 eyes screened, 37 eyes were included in the current study. With the
exception of outer plexiform layer/Henle ﬁber layer junction restoration, no signiﬁcant
changes regarding microstructural alterations between baseline and end of study were
encountered after long-term anti–vascular endothelial growth factor (disorganization of
retinal inner layers P = 0.381, outer plexiform layer/Henle ﬁber layer junction P = 0.001,
external limiting membrane/ellipsoid zone P = 0.524, retinal pigment epithelium/Bruch
complex P = 0.122, retinal atrophy P = 0.317). Best-corrected visual acuity signiﬁcantly
increased over the course of the study, corresponding to central retinal thickness and
intraretinal ﬂuid reduction (all P , 0.0001). The extent of microstructural alterations was
negatively correlated with best-corrected visual acuity (P , 0.05).
Conclusion: Apart from outer plexiform layer/Henle ﬁber layer junction layer restoration,
no effect on preexisting retinal alterations was encountered after long-term intravitreal
injections. Thus, intravitreal ranibizumab or aﬂibercept did not have a major effect (neither
positive nor negative) on microstructural alterations.
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Diabetic macular edema (DME) represents themajor cause of visual impairment among diabetic
patients, occurring in approximately 35% of patients
with diabetic retinopathy.1,2 Complex biochemical
pathways lead to microvascular dysfunction, in-
creased local inﬂammation and oxidative stress, re-
sulting in the accumulation of cytokines and growth
factors. This results in a breakdown of the blood–
retinal barrier and an accumulation of intraretinal
ﬂuid (IRF).3 The most important alterations at the
blood–retinal barrier include pericyte loss, thickening
of the basement membrane, and decreased intercel-
lular connections.4 Changes at the level of the pho-
toreceptors and the retinal pigment epithelium (RPE)
occur due to an accumulation of reactive oxygen
species and the impairment of vascular integrity.3 In
addition to the described vascular changes, alterations
at the neurovascular unit (Müller cells, astrocytes,
ganglion cells, amacrine cells, retinal vascular endo-
thelial cells, and pericytes) play a role in the patho-
genesis of DME.5 Recent reports consider diabetic
retinopathy as neurodegenerative disease.6
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Current treatment strategies for DME include intra-
vitreal anti–vascular endothelial growth factor (anti-
VEGF) agents, intravitreal steroid injections, and grid
laser photocoagulation. At present, anti-VEGF agents
represent the ﬁrst-line therapy option.7,8
Because DME mostly requires long-term treatment
and is often started rather early in life, the impact of
multiple intravitreal anti-VEGF injections on the retinal
microstructure is of great importance. A progression of
atrophic changes after long-term anti-VEGF exposure in
age-related macular degeneration was recently reported
by Schuetze et al.9 However, age-related macular de-
generation represents a disease with preexisting RPE
damage, comparison with DME may therefore not be
appropriate.10,11 Up to now, only a limited amount of
reports regarding the anatomical outcome after treatment
of DME with anti-VEGF agents exists.12,13 To the best
of our knowledge, the impact of long-term (.1 year)
exposure to intravitreal anti-VEGF on microstructural
alterations in DME has not yet been systematically
evaluated.
Currently it is unclear, if an assumed additional
deprivation of choroidal/retinal blood ﬂow, because
of long-term exposure to anti-VEGF (ranibizumab
and/or aﬂibercept), leads to a deterioration of preex-
isting retinal microstructural alterations. It is further
of interest whether decreasing IRF results into
a regression of microstructural alterations as imaged
by spectral-domain optical coherence tomography
(SD-OCT) and whether different microstructural alter-
ations are correlated with the functional outcome.
Spectral-domain optical coherence tomography pro-
vides high-resolution noncontact imaging of the retinal
substructures and allows for in vivo insight into the
pathogenesis of DME.
Several studies revealed an association between
functional outcomes and morphologic alterations
as visualized by OCT (integrity of external limiting
membrane [ELM], status of photoreceptor cone outer
segment tips,14 disorganization of retinal inner layers
[DRIL],15,16 hyperreﬂective foci 12 and photoreceptor
integrity,17 inter alia). Our study may elucidate
whether detrimental or positive effects of anti-VEGF
on preexisting microstructural alterations exist and
therefore be of relevance for the future management
of DME.
Material and Methods
This retrospective single-center study was con-
ducted at the Department of Ophthalmology, City
Hospital Triemli Zurich and was approved by the local
ethics committee (Ethics Commission of the Canton
Zurich, KEK-ZH-Nr. 2014-0601). Its conduction
adhered to the tenets of the Declaration of Helsinki.
Included patients gave their written informed consent
on retrospective data evaluation and its publication.
Data were retrieved from an internal database, con-
taining clinical information of all patients treated with
anti-VEGF agents during 2012 to 2016. In addition,
medical charts and SD-OCT scans of included patients
were reviewed.
Patients with a history of $ 20 intravitreal anti-
VEGF injections (aﬂibercept and/or ranibizumab) for
DME were included in the analysis. This results in an
exposure period of $ 20 months, as the minimum
injection interval was 1 month. At baseline (BL), pa-
tients were treatment naive regarding intravitreal anti-
VEGF. End of study (EOS) was deﬁned as the last
available follow-up. All intravitreal injections (IVIs)
were administered according to a treat-and-extend reg-
imen. This protocol is characterized by the adjustment
of individual injection intervals according to therapeu-
tic response.18
Patients with further degenerative or vascular
retinal diseases, ischemic maculopathy, vitreomacu-
lar traction syndromes, uncontrolled intraocular
pressure, signiﬁcant refractive media opacities,
inﬂammatory ocular diseases, focal laser treatment
and/or intravitreal steroid injections during the
observation period were excluded from the analysis.
Previous intravitreal steroid administration was not
deﬁned as exclusion criterion. Eyes with previous
bevacizumab injections were excluded because of
the lack of OCT data. Systemic data at BL (HbA1c,
type and duration of diabetic disease) were obtained
from existing medical records.
Spectral-domain optical coherence tomography
images (Heidelberg Spectralis System, central
foveal B-scan of 512 A–scans, 20° · 15°) were
evaluated at BL (before ﬁrst anti-VEGF injection)
and after $ 20 IVI for DRIL, alterations at the level
of the outer plexiform layer/Henle ﬁber layer
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junction (OPL/HE), integrity of external limiting
membrane/ellipsoid zone (ELM/EZ), disruption of
retinal pigment epithelium/Bruch complex (RPE/
BR), retinal atrophy (RA), and maximal IRF height.
Horizontal (DRIL, OPL/HE, ELM/EZ, RPE/BR, and
RA) and vertical IRF extensions (mm) of microstruc-
tural alterations were manually measured in the hori-
zontal central foveal scan using the integrated distance
measurement tool of the Heidelberg Spectralis system.
Two independent graders (ophthalmology residents
with considerable experience in OCT reading) under-
took measurements. Data of central retinal thickness
(CRT) were extracted from the thickness map
window of the computerized software of the
Heidelberg Spectralis system. An integrated eye
tracking system ensured the correct position for fol-
low-up.
Primary outcome was the extent of retinal micro-
structural alterations (DRIL, OPL/HE, ELM/EZ, and
RPE/BR) at BL versus after $ 20 IVI (i.e., EOS).
Best-corrected visual acuity (BCVA) and degree of
DME (CRT and IRF), as well as correlation analyses
of microstructural alterations and BCVA were deﬁned
as secondary outcome measures.
For statistical purposes, BCVA measures (regis-
tered as Snellen acuity fractions) were converted
into Early Treatment Diabetic Retinopathy Study
scores as described by Gregori et al.19 Statistical
analyses were performed using IBM SPSS statistics,
version 22 for Microsoft Windows. Kolmogorov–
Smirnov tests were conducted to test for data distribu-
tion. Wilcoxon signed rank tests and paired t-tests were
used for asymmetrical (EML/EZ, RPE/BR, RA, BCVA,
CRT, and IRF) and symmetrical distributions (DRIL and
OPL/HE) of differences, respectively. Pearson correlation
analyses, as well as a multivariate regression analysis
(analysis of variance) were used to study correlations
between BCVA and microstructural alterations. The
impact of previous retinal laser coagulation on micro-
structural alterations was tested using independent
samples Kruskal–Wallis tests. P-values , 0.05 were
considered as statistical signiﬁcant. The two independent
graders were masked as to clinical data and to the number
of injections. Interrater reliability was quantiﬁed by the
intraclass correlation coefﬁcient (two-sided, and mixed).
Results
Of 383 eyes screened, 37 eyes (n = 37) of 26 pa-
tients with DME met the inclusion criteria for the cur-
rent retrospective analysis. The study group consisted
of 16 male and 10 female patients. 29 eyes had non-
proliferative and eight eyes proliferative diabetic reti-
nopathy. Mean age at BL amounted to 61.43 ± 9.8
years. Mean duration of systemic diabetic disease
was indicated as 18.3 ± 9.1 years. Mean HbA1C at
BL amounted to 7.1% ± 2.3. Included eyes had a his-
tory of at least 20 IVI with aﬂibercept and/or ranibi-
zumab. Included patients received a total of 1,069
injections (695 ranibizumab and 374 aﬂibercept).
The treatment period with aﬂibercept and/or ranibi-
zumab ranged from 21 to 65 months (mean = 42.84,
SD ± 12.5, equals 3.5 ± 1 year). The mean number of
injections was 29.5 (SD ± 7.8). Four eyes (10.8%)
were pretreated with other agents (intravitreal triam-
cinolone [n = 3] and/or dexamethasone [n = 1]), 1
patient with subcutaneous canakinumab (n = 1).
Eighteen eyes (48.6%) underwent focal laser coagula-
tion, 15 eyes (40.5%) panretinal laser coagulation
before BL. See Table 1 for detailed patient
characteristics.
At BL, all included patients had retinal microstruc-
tural alterations (DRIL 97.3%, n = 36; OPL/HE 100%,
n = 37; ELM/EZ 64.9%, n = 24; RPE/BR 81.1%, n =
30; and RA 2.7%, n = 1). Figures 1 and 2 show micro-
structural alterations of a representative case at BL and
EOS. With the exception of OPL/HE restoration, no
signiﬁcant change regarding retinal microstructural al-
terations was encountered between BL and EOS (i.e.,
$ IVI 20). Detailed results are reported in Table 2.
Central retinal thickness at BL amounted to 451.5 ±
161.4 mm versus 288.7 ± 51.1 mm at EOS (P ,
0.0001). Intraretinal ﬂuid height at BL amounted to
250 ± 154.5 mm versus 69.1 ± 73.4 mm at EOS
(P , 0.0001). Mean BCVA signiﬁcantly increased
from 69.2 ± 11.6 letters at BL to 77.3 ± 7.4 at EOS
(P , 0.0001). The extent of retinal microstructural
alterations at BL was negatively correlated with BL
Table 1. Baseline Characteristics of Enrolled Patients
Age, years (mean ± SD) 61.4 ± 9.8
Sex, male/female, N 16/10
HbA1C % (mean ± SD) 7.1 ± 2.3
BCVA at BL (mean ± SD letters early
treatment diabetic retinopathy
study)
69.2 ± 11.6
Disease duration (years) 77.3 ± 7.4
Diabetic retinopathy type, N
Proliferative diabetic retinopathy 8
Nonproliferative diabetic
retinopathy
29
Previous IVIs, N
Triamcinolone 3
Dexamethasone 1
Canakinumab 1
Laser photocoagulation, N
Panretinal 15
Focal 18
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BCVA (Pearson correlation analyses: DRIL r =
20.362, P = 0.028; OPL/HE r = 20.452, P =
0.005; ELM/EZ r = 20.380, P = 0.020; and RPE/
BR r = 20.429, P = 0.008), as illustrated in Figure 3.
In addition, a multiple regression was run to predict
BCVA at BL from microstructural alterations
(DRIL, OPL/HE, ELM/EZ, and RPE/BR). These
variables statistically signiﬁcantly predicted BCVA,
F4, 36 = 2.686, P = 0.049, and R2 = 0.251. Previous
laser treatment had no effect on microstructural alter-
ations. Independent samples Kruskal–Wallis tests did
not reveal statistical signiﬁcant differences between the
three groups (no laser versus panretinal versus focal
laser) at BL and EOS (BL DRIL P = 0.294; BL OPL/
HE P = 0.305; BL ELM/EZ P = 0.525; BL RPE/BR P
= 0.676; EOS DRIL P = 0.699; EOS OPL/HE
P = 0.346; EOS ELM/EZ P = 0.420; and EOS RPE/BR
P = 0.511).
Statistical analysis demonstrated an overall intra-
class correlation coefﬁcient among the different
observers of 0.841 ± 0.12 (DRIL: 0.774 [95% con-
ﬁdence interval, CI: 0.56–0.88], OPL/HE: 0.834
[CI: 0.68–0.92], ELM/EZ: 0.908 [CI: 0.82–0.95],
RPE/BR: 0.689 [CI: 0.39–0.84], and RA: 0.99 [CI:
0.98–0.99]), indicating good to excellent interob-
server consistencies.20
Discussion
Diabetic macular edema is highly prevalent and
strongly associated with visual impairment. It there-
fore represents a condition of major medical and
socioeconomic impact.21 Different and overlapping
pathophysiologic mechanisms such as microvascular
dysfunction with subsequent local inﬂammation and
oxidative stress, as well as alterations at the neurovas-
cular unit have been proposed.3 Recently, it was re-
ported that neurodegenerative changes may precede
clinically visible vascular changes.22,23
Anti–vascular endothelial growth factor therapy
currently represents the gold standard therapy leading to
an amelioration of the vascular integrity, without sig-
niﬁcant effect on inﬂammatory or neuronal pathways.24
Our data indicate that long-term intravitreal anti-
VEGF (.20 months) therapy does not lead to a signiﬁ-
cant progression of preexisting microstructural alterations
(DRIL, ELM/EZ, RPE/BR, and RA). Intravitreal aﬂiber-
cept and/or ranibizumab seem to neither deteriorate nor
have the capability to improve microstructural alterations
(apart from CRT reduction and OPL/HE restoration). In
contrast to Seo et al,13 who report about a continuous
restoration of ELM/EZ integrity after ranibizumab treat-
ment (follow-up of 12 months), we solely found
Fig. 1. Representative case with
microstructural alterations on
SD-OCT at BL.
Fig. 2. Representative case
with microstructural alterations
after 21 intravitreal anti-VEGF
injections.
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a restoration of OPL/HE layers. However, in the cited
study, microstructural alterations have only been catego-
rized (“well delineated” vs. “disrupted”) and measured
centrally (central 1 mm). Paracentral or short segment
alterations may therefore have been missed. Consistent
with our results, Shin et al found no change of retinal
nerve ﬁber layer thickness after multiple intravitreal anti-
VEGF injections in the eyes with diabetic retinopathy.25
Regarding the complex pathophysiology of DME
and the herein involved pathways, VEGF blockage thus
seems to solely play a minor role in the overall integrity
of retinal microstructures. Further studies evaluating the
impact of intravitreal steroids (involved in multiple
pathways of disease development) on microstructural
alterations compared with anti-VEGF would be of great
interest. However, building on the theory of diabetic
retinopathy as neurodegenerative disease, one would
rather expect degenerative neurosensory changes to be
irreversible.
There is of course no doubt regarding the efﬁcacy of
anti-VEGF agents in IRF reduction and visual acuity
gains; however, preexisting microstructural alterations
should be taken into account once functional outcomes
are predicted.
In agreement with previous studies,13,15,17 we found
a correlation between BCVA and the extent of micro-
structural alterations. Microstructural alterations may
serve as predictors for unfavorable functional outcome
to a various extent. Our study did reveal a stronger cor-
relation of outer microstructural alterations (i.e., RPE/BR,
ELM/EZ, and OPL/HE) with BCVA than that of inner
retinal layers (DRIL). This may be seen in the context of
photoreceptor involvement and a presumed neuroplastic
potential of neural circuits in retinal inner layers.
Table 2. Microstructural Alterations at BL Versus at EOS (After $20 Intravitreal Anti-VEGF Injections), P-values for
Differences
Microstructural Alteration Type BL (Mean ± SD) EOS (Mean ± SD) P
DRIL 2,228.5 ± 1,023.1 2,093.22 ± 958.0 0.381
OPL/HE 3,740.7 ± 1,296.9 3,158.81 ± 1,045.6 0.001
ELM/EZ 919.5 ± 1,302.0 648.4 ± 710.4 0.524
RPE/BR 1,063.2 ± 1,065.0 864.4 ± 721.9 0.122
RA 33.4 ± 203.0 33.5 ± 203.9 0.317
Fig. 3. Correlation of BCVA
and microstructural alterations.
Disorganization of retinal inner
layers r = 20.362, P = 0.028;
alterations at the level of the
OPL/HE r = 20.452, P = 0.005;
integrity of ELM/EZ r =
20.380, P = 0.020; disruption of
RPE/BR r = 20.429, P = 0.008.
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Previous laser treatment did not affect the size of
microstructural alterations to a signiﬁcant extent. This
may be seen in the context, which no actual laser scars
lay in the measured areas and that the 3 compared
groups (no laser versus panretinal laser versus focal
laser) were fairly small and inhomogeneously split.
Limitations
The small number of patients, the lack of a control
group, and the retrospective study design should be
mentioned as potential and important sources of bias.
Optical coherence tomography measurements were not
automated, and only central horizontal scans were
evaluated. Graders did not undergo a speciﬁc training
for OCT analysis. Image quality and presence of IRF
inﬂuenced the accuracy of manual measurements to
a certain degree.
Conclusion
In conclusion, intravitreal ranibizumab and aﬂiber-
cept seems neither to have detrimental nor positive
effects on microstructural alterations, with the known
reduction of CRT but without relevant impact on
restoration or promotion of retinal layer disruption.
Alterations of the retinal microarchitecture are associ-
ated with unfavorable functional outcome in patients
with DME and should be taken into account once
visual acuity gains are predicted.
Key words: diabetic macular edema, vascular endo-
thelial growth factor, ranibizumab, aﬂibercept, retinal
layers, optical coherence tomography.
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